Sökning: "Ann-Charlotte Nedlund"

Visar resultat 1 - 5 av 6 avhandlingar innehållade orden Ann-Charlotte Nedlund.

  1. 1. Designing for Legitimacy : Policy Work and the Art of Juggling When Setting Limits in Health Care

    Författare :Ann-Charlotte Nedlund; Peter Garpenby; Roine Johansson; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Health care; limit-setting; legitimacy; policy work; mediating institutions; sense making; governance;

    Sammanfattning : Limit-setting in publicly funded healthcare is unavoidable, and increasingly important in the governance and management of the demand for health services. The work of limit-setting takes place in the organising of the provision of health services, where various health workers (professionals, administrators, unit managers, politicians) collectively exercise their skills. LÄS MER

  2. 2. The matter of economic evaluations in health policy decision-making : The case of the Swedish national guidelines for heart diseases

    Författare :Nathalie Eckard; Lars-Åke Levin; Magnus Janzon; Ann-Charlotte Nedlund; Clas Rehnberg; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES;

    Sammanfattning : Economic evaluations are used to inform decision makers about the efficient allocation of scarce healthcare resources and are generated with the direct intent to support decisions in healthcare. Producing guidelines is a complex process and the inclusion of health-economic aspects in the formulation of the Swedish national guidelines as a basis for the written recommendations (priority gradings), distinguishes them from their European counterparts. LÄS MER

  3. 3. Promises and pitfalls of value-based reimbursement in healthcare : A mixed method health economic approach

    Författare :Thérèse Eriksson; Lars-Åke Levin; Hans Tropp; Ann-Britt Wiréhn; Ann-Charlotte Nedlund; Claes Rehnberg; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES;

    Sammanfattning : Financial incentives can be an effective tool to influence behaviour in almost any context and healthcare is no exception. The healthcare market is, however complex, characterised by uncertainty, information asymmetry and multiple agency connections. The reach and limits of financial incentives in healthcare has been widely debated for decades. LÄS MER

  4. 4. Social citizenship and people with dementia : Designing social care policies in Sweden

    Författare :Jonas Nordh; Lars-Christer Hydén; Ann-Charlotte Nedlund; Charlotte Clarke; Linköpings universitet; []
    Nyckelord :SAMHÄLLSVETENSKAP; SOCIAL SCIENCES; SAMHÄLLSVETENSKAP; SOCIAL SCIENCES; SAMHÄLLSVETENSKAP; SOCIAL SCIENCES; SAMHÄLLSVETENSKAP; SOCIAL SCIENCES; HUMANIORA; HUMANITIES; Social citizenship; people with dementia; policy; policy practice; policy actors; street-level bureaucrats; social work; care managers; rights; Socialt medborgarskap; personer med demenssjukdom; policy; policypraktik; gräsrotsbyråkrater; socialt arbete; biståndshandläggare;

    Sammanfattning : People with dementia are commonly in need of some form of social care from the social services in order to manage their everyday situations. However, social services are shaped by the construction of policy targets. The aim of this dissertation is to explore the social citizenship for people with dementia. LÄS MER

  5. 5. Healthcare Priority Setting and Rare Diseases : What Matters When Reimbursing Orphan Drugs

    Författare :Johanna Wiss; Gustav Tinghög; Per Carlsson; Lars-Åke Levin; Ann-Charlotte Nedlund; Joanna Coast; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; SAMHÄLLSVETENSKAP; SOCIAL SCIENCES;

    Sammanfattning : The rarity of a disease can give rise to challenges that differ from conventional diseases. For example, rarity hampers research and development of new drugs, and patients with severe, rare diseases have limited access to qualified treatments. When drugs are available, clinical evidence has higher uncertainty and the drugs can be very expensive. LÄS MER